Novocure announced that the results of its INNOVATE phase 2 pilot trial have been published in Gynecologic Oncology. The INNOVATE trial was a prospective, single-arm study testing the feasibility, safety and preliminary efficacy of Tumor Treating Fields combined with weekly paclitaxel in recurrent ovarian cancer. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. Progression free survival of recurrent ovarian cancer patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls. Median progression free survival in the Tumor Treating Fields-treated group was 8.9 months and median overall survival was not yet reached. Median one-year survival in the Tumor Treating Fields-treated group was 61%. The median compliance of patients with Tumor Treating Fields in the first three months of treatment was 77%. Two cases of severe skin irritation due to Tumor Treating Fields were reported. No other serious device-related adverse events were reported.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.